#616
|
|||
|
|||
Ê ñîæàëåíèþ íåò ôóëë-òåêñòà, ññûëêà íà àáñòðàêò:
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Ìû áîëüíûì, íóæäàþùèìñÿ â îðàëüíîé àíòèêîàãóëÿöèè, íàçíà÷àåì êëîïèäîãðåëü è ìàðêóìàð (ôåíïðîêóìîí), â çàâèñèìîñòè îò òèïà ñòåíòà ÷åðåç 1-6 ìåñÿöåâ îòìåíÿåì êëîïèäîãðåëü, áîëüíûå îñòàþñÿ òîëüêî íà ìàðêóìàðå. Ýòî îêîëî 300 ïàöèåíòîâ ñ DES è íå ìàëî ñ BMS. Ðåçóëüòàòû ãðóïïû ñ DES â âèäå ðåòðîñïåêòèâíîãî àíàëèçà ïîêà íå îïóáëèêîâàíû, òàê ÷òî òî÷íûå öèôðû íàçûâàòü íå áóäó, ãðóïïû êîíòðîëÿ íåò, íî ïî ñðàâíåíèþ ñ ëèòåðàòóðíûìè äàííûìè ó íàñ íå ïîâûñèëèñü ðèñêè òðîìáîçîâ è ñíèçèëèñü ðèñêè êðîâîòå÷åíèé. Ðèñêè òðîìáîçîâ ìû àíàëèçèðîâàëè íå òîëüêî âî âðåìÿ äâîéíîé òåðàïèè, íî è â îòäàëåííîì ïåðèîäå, íà ôîíå òåðàïèè àíòèêîàãóëÿíòîì. Òóò, êîíå÷íî, íè îäíîãî íîâîãî îðàëüíîãî àíòèêîàãóëÿíòà, ïðîñòî â íàøåì îïûòå ýôôåêòèâíàÿ îðàëüíàÿ àíòèêîàãóëÿöèÿ ó áîëüíûõ ñ ÈÁÑ, â íåé íóæäàþùèõñÿ, ïîëó÷èëàñü äîñòàòî÷íîé áåç äîïîëíèòåëüíîé àíòèàãðåãàöèè |
#617
|
||||
|
||||
Öèòàòà:
Among the phase 3 trials, 627 patients in the dabigatran arm had major bleeding vs 407 in the warfarin age. Patients in the dabigatran arm were older, 75.3 years vs 71.8 years in the warfarin arm (P<0.0001), and two thirds of the patients were male (64.4% vs 65.9%). “Patients with major bleeds on dabigatran were older, had lower creatinine clearance, and had more frequent use of aspirin or nonsteroidal antiinflammatory agents than those on warfarin,” Dr. Majeed said. In the RE-LY study, 439 of 741 patients (59.2%) had major bleeds transfused with red cells vs 210 of 421 patients (49.9%) on warfarin (P=0.002). However, those on warfarin required more fresh frozen plasma transfusions (30.2% vs 19.8%; P<0.001) and more vitamin K for bleeding management (27.3% vs 9.4%; P<0.001) than those on dabigatran. Mean length of stay in intensive care was 2.7 days for those on warfarin vs 1.0 days for those on dabigatran (P=0.01). A total of 15% of patients on warfarin had bleeds requiring surgery vs 12.2% with dabigatran (P=0.017). Recombinant factor VIIa was used for eight patients treated with dabigatran and three with warfarin (P=0.53). Outcomes based on event reports from the five phase 3 trials found a reduced risk for death with dabigatran vs warfarin during 30 days from bleeding (P=0.052). Mortality did not differ significantly based on age, creatinine clearance, or use of aspirin. “Despite the unavailability of a specific antidote against dabigatran, the overall resources required to manage bleeding are not greater,” Dr. Majeed concluded. “More frequent transfusion with red cells is counterbalanced by shorter stay in the intensive care unit and less frequent transfusion of plasma.” [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#618
|
||||
|
||||
WOEST ïîêàçàë, ÷òî äâîéíàÿ òåðàïèÿ ëó÷øå òðîéíîé. Íî ïðî íîâûå ÀÊ ðå÷ü íå øëà.
|
#620
|
|||
|
|||
íó âîçìîæíî, ýòà èíôîðìàöèÿ â èñõîäíîì âîïðîñå áûëà ïðîñòî ëèøíåé. À òàê - êàê è äðóãèì ïàöèåíòàì ñî ñòàáèëüíîé ÈÁÑ, ïàöèåíòó ñî ñòåíòàìè ïîêàçàí ïðèåì ëèáî àñïèðèíà, ëèáî êëîïè íåîïðåäåëåííî äîëãî. Åùå ïèøóò, ÷òî ñ DES áûâàåò late stent malapposition è î÷åíü ïîçäíèé òðîìáîç ñòåíòà, õîòÿ ñ ñîâðåìåííûìè DES âðîäå ýòî î÷åíü ðåäêî, íî âñå-òàêè ýòî ðèñê, õîòÿ è ìèíèìàëüíûé, íî äîïîëíèòåëüíûé ê îáû÷íîìó ðèñêó ïàöèåíòîâ ñî ñòàáèëüíîé ÈÁÑ.
|
#621
|
||||
|
||||
Öèòàòà:
Öèòàòà:
|
#622
|
||||
|
||||
Ïðè ñòàáèëüíîé ÈÁÑ ïðè íàëè÷èè ïîêàçàíèé ê ïðèåìó àíòèêîàãóëÿíòîâ, ñòîèò íàçíà÷àòü àíòèêîàãóëÿíòû. Âîïðîñ âûáîðà ìåæäó âàðôàðèíîì è íîâûìè ÀÊ îñòàåòñÿ "ñåðîé çîíîé". Íà ôîíå ïðèåìà äàáèãàòðàíà ÷àñòîòà ÈÌ áûëà âûøå, ÷åì íà âàðôàðèíå, à íà ôîíå ïðèåìà ðèâàðîêñàáàíà è àïèêñàáàíà - íèæå. Íî âñå ýòî íåäîñòîâåðíî. Äà è äàííûå ïîëó÷åíû íà äðóãîé ïîïóëÿöèè.
|
#623
|
||||
|
||||
#624
|
|||
|
|||
Âèäèìî, íà "íå ÈÁÑ-íîé":-)
Íåèíôåðèîðíûå èññëåäîâàíèÿ ïî íîâûì àíòèêîàãóëÿíòàì èìååþò ðÿä ïðåèìóùåñòâ è ðÿä îãðàíè÷åíèé. Íî ðåçóëüòàòû èõ ìîæíî òðàêòîâàòü â ñîîòâåòñòâèè ñ äèçàéíîì ïðèìåðíî òàê: äàáèãàòðàí (è êîìïàíèÿ) íå õóæå, ÷åì âàðôàðèí. Ñïåêóëÿöèè íà òåìó "à íå ëó÷øå ëè?" îñòàþòñÿ ñïåêóëÿöèÿìè. |
#625
|
||||
|
||||
Íåèíôåðèîðíûå èññëåäîâàíèÿ âïîëíå ïîçâîëÿþò ñêàçàòü ÷òî ëó÷øå, áåç ñïåêóëÿöèé. À âîò ñóïåðèîðíûå èññëåäîâàíèÿ ïðè ðàâåíñòâå ðåçóëüòàòîâ, íå ïîçâîëÿþò ñêàçàòü "íå õóæå".
Âîçìîæíûå çàêëþ÷åíèÿ ïî ðåçóëüòàòàì íåèíôåðèîðíûõ èññëåäîâàíèé [Èçîáðàæåíèÿ äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì] |
#626
|
|||
|
|||
Öèòàòà:
|
#627
|
||||
|
||||
Íå ñîâñåì òàê, ìíå êàæåòñÿ. Õóæå è ëó÷øå ñêàçàòü ìîæíî. Îñòàíàâëèâàþò æå èññëåäîâàíèÿ äîñðî÷íî çà ÿâíûì ïðåèìóùåñòâîì îäíîé èç ãðóïï. Òàê è çäåñü. Âïîëíå ìîæíî ãîâîðèòü, ÷òî ïî êàêèì-òî ïîçèöèÿì âàðôàðèí õóæå. Èññëåäîâàíèå æå ïëàíèðóåòñÿ êàê íîíèíôåðèîðíîå, åñëè åñòü êàêèå-òî äîïîëíèòåëüíûå ïðåèìóùåñòâà.  ñëó÷àå íîâûõ àíòèêîàãóëÿíòîâ - îòñóòñòâèå íåîáõîäèìîñòè ðåãóëÿðíîãî ëàáîðàòîðíîãî êîíòðîëÿ.
|
#628
|
||||
|
||||
...... à ìîæíî íà êîíêðåòíîì ïðèìåðå?
Ñêàæèòå, ëþäè äîáðûå. Ïî÷åìó íà îñíîâàíèè îäíîãî íîí-èíôåðèîðíîãî ìóëüòèöåíòðîâîãî èññëåäîâàíèÿ PLATO, òèêàãðåëîð âî âñåõ ãàéäàõ ïîñòàâëåí "âûøå" êëîïèäîãðåëà? |
#629
|
||||
|
||||
âîïðîñ: ïîñòóïàåò ïàöèåíò ñ ïàðîêñèçìîì ôèáðèëëÿöèè, äëÿùèìñÿ îäèí äåíü, àíòèêîàãóëÿíòîâ íå ïðèíèìàë ðàíåå íèêîãäà, ïðèñòóïû ðàç â ïîëãîäà, ñïîíòàííî êóïèðóþòñÿ ÷åðåç 2-3 äíÿ, ðèñê ïî chads2vasc 3. Åñëè ÿ åãî ïðèíèìàþ êàê äåæóðíûé âðà÷ äîëæíà ëè ÿ íàçíà÷èòü âàðôàðèí íà ñëåäóþùèé äåíü, ó÷èòûâàÿ ÷òî íà äàëüíåéøåì àìáóëàòîðíîì ýòàïå îí åãî ïðèíèìàòü íå áóäåò (íî ïî ñóòè ýòî íå ìîè ïðîáëåìû, òàê êàê ÿ íå áóäó ïî îêíî÷àíèè äåæóðñòâà ñ÷èòàòüñÿ ëå÷àùèì âðà÷îì)? Êàê áûòü ñ ãåïàðèíîì (â ðåêîìåíäàöèÿõ òîëüêî âàðôàðèí)? íóæåí èëè íåò? Áîëüøå èíòåðåñóåò ôîðìàëüíàÿ ñòîðîíà âîïðîñà. Ïðîñòèòå çà ñóìáóðíîå èçëîæåíèå.
|
#630
|
|||
|
|||
Öèòàòà:
Öèòàòà:
For patients with AF <48 h and at high risk of stroke, i.v. heparin or weight-adjusted therapeutic dose LMWH is recommended peri-cardioversion, followed by OAC therapy with a VKA (INR 2.0–3.0) long term. IB |